A detailed history of Parallel Advisors, LLC transactions in Chinook Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 5 shares of KDNY stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5
Previous 5 -0.0%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 20, 2024

SELL
$0.0 - $40.39 $0 - $848
-21 Reduced 80.77%
5 $0
Q3 2023

Nov 13, 2023

SELL
$0.0 - $40.39 $0 - $848
-21 Reduced 80.77%
5 $0
Q2 2023

May 20, 2024

SELL
$18.66 - $38.58 $578 - $1,195
-31 Reduced 54.39%
26 $0
Q2 2023

Aug 04, 2023

SELL
$18.66 - $38.58 $578 - $1,195
-31 Reduced 54.39%
26 $0
Q1 2023

May 20, 2024

BUY
$21.53 - $26.8 $1,119 - $1,393
52 Added 1040.0%
57 $1,000
Q1 2023

Apr 25, 2023

BUY
$21.53 - $26.8 $366 - $455
17 Added 42.5%
57 $1,000
Q3 2022

Nov 10, 2022

BUY
$17.51 - $23.37 $245 - $327
14 Added 53.85%
40 $1,000
Q2 2022

Aug 01, 2022

BUY
$12.59 - $18.8 $264 - $394
21 Added 420.0%
26 $0
Q4 2020

Feb 02, 2021

BUY
$11.9 - $20.91 $59 - $104
5 New
5 $0

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.